Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men.
Simon ThonsgaardTimothy C R PrickettLasse H HansenNicolai J Wewer AlbrechtsenUlrik Ø AndersenDijana TerzicPeter PlomgaardFinn GustafssonJens P GoetzePeter D MarkPublished in: Clinical chemistry (2022)
Sacubitril/valsartan augments circulating concentrations of both bioactive CNP and NT-proCNP in healthy young men. The increase in bioactive CNP is most likely caused by de novo synthesis and secretion rather than diminished breakdown through neprilysin inhibition.ClinicalTrials.gov registration number NCT03717688.